
Researchers at Australia's QIMR Berghofer Medical Research Institute have achieved a breakthrough in creating a vaccine against the Epstein-Barr virus (EBV), which causes mononucleosis and can lead to cancer and multiple sclerosis. The vaccine targets lymph nodes in mice, generating strong and long-lasting antibodies and T cells that combat EBV. It also offers immunity against EBV-associated tumors, preventing secondary issues like brain inflammation linked to MS. The innovative approach combines antibodies and T cells to enhance immune response. Clinical trials may begin by 2024 or 2025. The study sheds light on why EBV affects people differently, providing hope for effective prevention.
Like
Save
Share